11/21/17 Lomustine and Bevacizumab in Progressive Glioblastoma.
These results were disappointing. Last year, the data was presented that this combination worked very well. This year they are saying that although there is a a relatively large improvement in progression free survival (from 1.5 months with the Lomustine (CCNU) alone to 4.2 months with the combination of Lomustine and Bevacizumab (Avastin), there was little (less than a month) improvement in overall survival.
11/17/17 Toca 5 Trial is now open!
I went to an impressive presentation by Tocagen today at the SNO meeting! They have a few long term survivors who not only are survivors, but have been able to return to work and lead productive lives. The phase 3 trial opened yesterday.
11/17/17 GBM Heroes Honored By CURE
Thanks to Cure Magazine, Novocure, Dr Sumrall, as well as my wife and kids - without whom I wouldn't have been able to do this!
11/07/17 Liquid Biopsy Spots Aggressive Pediatric Brainstem Cancer Earlier
This blood (and spinal fluid) test can help diagnose and monitor the response to treatment for these devastating tumors. There are drugs under development which target the marker mentioned, so this blood test might be able to be used to determine which patients get these new drugs, without the need for biopsies. Amazing stuff. And we are proud to say we are one of the sponsors. Your donations at work!
10/28/17 Durable Responses Observed in Recurrent
High Grade Glioma (rHGG) with Toca 511 &
Toca FC Treatment
This is a presentation about the Toca 511 / Toca FC trial. There are 6 long term survivors (4 GBM, 2 AA), all of whom had a complete response, And once they achieve a complete response, NONE had a recurrence. We never use the word "cured" when talking about a GBM, but having a clear scan for over 3 years makes us think it is possible a few of these patients may have been cured. It is only a small % at this time - 43% have some benefit from the treatment, and 20% have a significant response. Hopefully it will only get better and this may lead to a major breakthrough.
The Musella Foundation was an early supporter of this research (and they acknowledge us on the presentation:)